Compared to LOXL2 inhibition, treatment with a monoclonal antibody targeting specifically LOX did not alter liver fibrosis scores13, suggesting LOXL2 to be the superior target of antifibrotic therapy in these organs. Here, LOX is linked to Hepatic fibrosis.